Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. (Q38531069)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

title

Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

Fernando Cabanillas

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

3

Giralt SA

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

15

Champlin R

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

6

Khouri IF

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

author name string

Mehra RC

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

Kantarjian HM

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

Pugh WC

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

Moon Y

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

Williams P

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

Andersson BS

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

Przepiorka D

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

McCarthy PL

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

Gajewski JL

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

Deisseroth AB

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

language of work or name

English

0 references

publication date

1 March 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Medicine

16 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

volume

100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

page(s)

299-307

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

16 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Treatment of non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Intermediate lymphocytic lymphoma: clinical and pathologic features of a recently characterized subtype of non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

What's the deal with follicular lymphomas?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

High-dose melphalan and total body irradiation with bone marrow transplantation for refractory malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Allogeneic bone marrow transplantation for leukemia following piperazinedione and fractionated total body irradiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Which patients with relapsed non-Hodgkin's lymphoma benefit from high-dose therapy and hematopoietic stem-cell transplantation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Clinical studies of ABMT in non-Hodgkin's lymphoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

The role of autologous bone marrow transplantation in 46 adult patients with non-Hodgkin's lymphomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

High-dose chemotherapy, fractionated total-body irradiation, and allogeneic marrow transplantation for malignant lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European Group for Bone Marrow Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

CHOP-Bleo plus interferon for stage IV low-grade lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

Allogeneic bone marrow transplantation in adults with Burkitt's lymphoma or acute lymphoblastic leukemia in first complete remission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989488-0

10.1016/S0002-9343(97)89488-0

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8629675%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

1 reference